A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

July 17, 2026 updated by: Hutchmed

A Phase III Randomized, Double-Blind, Positive Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HMPL-760 in Combination With R-GemOx Versus Placebo in Combination With R-GemOx in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

This is a Phase III randomized, double-blind, positive controlled study to evaluate the efficacy, safety, and pharmacokinetics of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with R/R DLBCL.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The study phases include screening period, treatment period, safety observation period, PFS follow-up period, and OS follow-up period.

The target population of this study includes patients with DLBCL who are relapsed or refractory.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
240

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • China
      • Baoding, China
        • Recruiting
        • Baoding No.1 Central Hospital
        • Contact:
        • Principal Investigator:
          • Haiying Yao
      • Beijing, China
        • Recruiting
        • Beijing Tongren Hospital, Capital Medical University
        • Principal Investigator:
          • Liang Wang
        • Contact:
      • Beijing, China
        • Recruiting
        • Beijing GoBroad Hospital
        • Principal Investigator:
          • Kai Hu
        • Contact:
      • Bengbu, China
        • Recruiting
        • the First Affiliated Hospital of Bengbu Medical College
        • Contact:
        • Principal Investigator:
          • Yanli Yang
      • Changchun, China
        • Recruiting
        • The First Hospital of Jilin University
        • Principal Investigator:
          • Ou Bai
        • Contact:
      • Changsha, China
        • Recruiting
        • Hunan Cancer Hospital
        • Principal Investigator:
          • Hui Zhou
        • Contact:
      • Changsha, China
        • Recruiting
        • The Second Xiangya Hospital of Central South University
        • Principal Investigator:
          • Hongling Peng
        • Contact:
      • Changsha, China
        • Recruiting
        • People's Hospital of Hunan Province
        • Contact:
        • Principal Investigator:
          • Can Liu
      • Chengdu, China
        • Recruiting
        • West China Hospital of Sichuan University
        • Principal Investigator:
          • Liqun Zou
        • Contact:
      • Chengdu, China
        • Recruiting
        • Sichuan Provincial People's Hospital
        • Contact:
        • Principal Investigator:
          • Xiaobing Huang
      • Chongqing, China
        • Not yet recruiting
        • The First Affiliated Hospital of Chongqing Medical University
        • Principal Investigator:
          • Xin Wang
        • Contact:
      • Chongqing, China
        • Recruiting
        • Chongqing University Cancer Hospital
        • Principal Investigator:
          • Yao Liu
        • Contact:
      • Fujian, China
        • Recruiting
        • Quanzhou First Hospital.Fujian
        • Contact:
        • Principal Investigator:
          • Xiongpeng Zhu
      • Fuzhou, China
        • Recruiting
        • Fujian Medical University Union Hospital
        • Principal Investigator:
          • Jianzhen Shen
        • Contact:
      • Guangzhou, China
        • Recruiting
        • Sun Yat-sen University Cancer Center
        • Principal Investigator:
          • Zhiming Li
        • Contact:
      • Guangzhou, China
        • Not yet recruiting
        • Guangdong Provincial People's Hospital
        • Contact:
        • Principal Investigator:
          • Xiaojuan Wei
      • Guangzhou, China
        • Recruiting
        • ZhuJiang Hospital of Southern Medical University（The Second Clinical Medical College）
        • Principal Investigator:
          • Yuhua Li
        • Contact:
      • Guiyang, China
        • Recruiting
        • The Affiliated Hospital of Guizhou Medical University
        • Principal Investigator:
          • Yan Zhang
        • Contact:
      • Hangzhou, China
        • Recruiting
        • Zhejiang Cancer Hospital
        • Principal Investigator:
          • Haiyan Yang
        • Contact:
      • Hangzhou, China
        • Not yet recruiting
        • The First Affiliated Hospital, Zhejiang University
        • Principal Investigator:
          • Zhen Cai
        • Contact:
      • Harbin, China
        • Recruiting
        • Harbin Medical University Cancer Hospital
        • Contact:
        • Principal Investigator:
          • Qingyuan Zhang
      • Hefei, China
        • Recruiting
        • The Second Affiliated Hospital of Anhui Medical University
        • Contact:
        • Principal Investigator:
          • Zhimin Zhai
      • Jinan, China
        • Not yet recruiting
        • Qilu Hospital of Shandong University
        • Contact:
        • Principal Investigator:
          • Shuqian Xu
      • Jinan, China
        • Recruiting
        • Shandong Cancer hospital & institute
        • Principal Investigator:
          • Zengjun Li
        • Contact:
      • Kunming, China
        • Not yet recruiting
        • The First Affiliated Hospital of Kunming Medical University
        • Contact:
        • Principal Investigator:
          • Mingxia Shi
      • Nanchang, China
        • Recruiting
        • Jiangxi Cancer Hospital
        • Principal Investigator:
          • Yan Huang
        • Contact:
      • Nanjing, China
        • Recruiting
        • Jiangsu Cancer Hospital
        • Principal Investigator:
          • Yan Zhang
        • Contact:
      • Nanjing, China
        • Not yet recruiting
        • Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School
        • Contact:
        • Principal Investigator:
          • Jingyan Xu
      • Nanning, China
        • Recruiting
        • The First Affiliated Hospital of Guangxi Medical University
        • Principal Investigator:
          • Zhigang Peng
        • Contact:
      • Qingdao, China
        • Recruiting
        • The Affiliated Hospital of Qingdao University
        • Contact:
        • Principal Investigator:
          • Xia Zhao
      • Shanghai, China
        • Recruiting
        • Ruijin Hospital, Shanghai Jiaotong University School of Medicine
        • Principal Investigator:
          • Weili Zhao
        • Contact:
      • Shanghai, China
        • Recruiting
        • Tongji Hospital of Tongji University
        • Contact:
        • Principal Investigator:
          • Ping Li
      • Shenyang, China
        • Not yet recruiting
        • Shengjing Hospital of China Medical University
        • Principal Investigator:
          • Wei Yang
        • Contact:
      • Shenzhen, China
        • Not yet recruiting
        • Shenzhen People's Hospital
        • Principal Investigator:
          • Jihao Zhou
        • Contact:
      • Taiyuan, China
        • Recruiting
        • Shanxi Provincial Cancer Hospital
        • Principal Investigator:
          • Liping Su
        • Contact:
      • Tangshan, China
        • Recruiting
        • North China University of Science and Technology Affiliated Hospital
        • Contact:
        • Principal Investigator:
          • Zhenyu Yan
      • Tianjin, China
        • Recruiting
        • Tianjin Medical University Cancer Institute & Hospital
        • Principal Investigator:
          • Zhengzi Qian
        • Contact:
          • Zhengzi Qian
          • Phone Number: 13702031222
          • Email: qzz@163.com
      • Tianjin, China
        • Recruiting
        • Tianjin People's Hospital
        • Contact:
        • Principal Investigator:
          • Xingli Zhao
      • Tianjin, China
        • Recruiting
        • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
        • Principal Investigator:
          • Dehui Zou
        • Contact:
      • Wenzhou, China
        • Not yet recruiting
        • The First Affiliated Hospital of WMU
        • Contact:
        • Principal Investigator:
          • Songfu Jiang
      • Wuhan, China
        • Recruiting
        • Hubei Cancer Hospital
        • Principal Investigator:
          • Huijing Wu
        • Contact:
      • Wuhan, China
        • Recruiting
        • Wuhan Union Hospital of China
        • Principal Investigator:
          • Liling Zhang
        • Contact:
      • Xi'an, China
        • Recruiting
        • The First Affiliated Hospital of Xi'an Jiaotong University
        • Principal Investigator:
          • Pengcheng He
        • Contact:
      • Xi'an, China
        • Not yet recruiting
        • The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hosiptal)
        • Principal Investigator:
          • Jie Liu
        • Contact:
      • Xiamen, China
        • Not yet recruiting
        • The First Affiliated Hospital of Xiamen University
        • Principal Investigator:
          • Bing Xu
        • Contact:
      • Xuzhou, China
        • Not yet recruiting
        • The Affiliated Hospital of Xuzhou Medical University
        • Contact:
        • Principal Investigator:
          • Wei Sang
      • Zhengzhou, China
        • Recruiting
        • Henan Cancer Hospital
        • Principal Investigator:
          • Keshu Zhou
        • Contact:
      • Zhengzhou, China
        • Recruiting
        • The First Affiliated Hospital of Zhengzhou University
        • Contact:
        • Principal Investigator:
          • Xudong Zhang
      • Ürümqi, China
        • Not yet recruiting
        • People's Hospital of Xinjiang Uygur Autonomous Region
        • Principal Investigator:
          • Yan Li
        • Contact:
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China
        • Recruiting
        • Fudan University Shanghai Cancer Center
        • Contact:
        • Principal Investigator:
          • Fangfang Lv

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Sign the ICF and be able to follow the requirements of study protocol;
  2. Age ≥18 years;
  3. ECOG performance status score between 0 and 2;
  4. Histopathologically confirmed diagnosis of DLBCL;
  5. The investigator judges that the patient's current condition requires further treatment;
  6. Patients should have at least one bi-dimensionally measurable lesion;
  7. Expected survival is more than 12 weeks;

Exclusion Criteria:

  1. Patients with known primary or secondary central nervous system lymphoma (CNSL) or the presence of clinical symptoms suggestive of CNSL;
  2. Women who are pregnant (positive pregnancy test during the screening period) or breastfeeding;
  3. Organ insufficiency;
  4. Currently known history of liver disease, including cirrhosis, alcoholic liver, known active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV);
  5. History of significant organ bleeding, including gastrointestinal bleeding, hematencephalon, haemoptysis, etc., within 8 weeks prior to the first dose of study drug;
  6. Known risk of bleeding, such as coagulation factor deficiency, vascular hemophilia; or the patient is receiving vitamin K antagonist (warfarin);
  7. The toxic reactions of previous anti-tumor therapy have not recovered to the level of ≤ grade 1 (except for alopecia and decreased appetite and other conditions that have been clearly required in the inclusion and exclusion criteria);
  8. Clinically significant active infection;

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: The experimental group
Patients will receive HMPL-760 once daily (QD) orally in combination with R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.
Drug: HMPL-760
Patients will receive HMPL-760 once daily (QD) orally.
Drug: R-GemOx
R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.
Other Names:
  • Gemcitabine Hydrochloride for Injection
  • Rituximab Injection
  • Oxaliplatin Injection
Placebo Comparator: The control group
Placebo QD at the same dose as HMPL-760 in the experimental group will be given in the control group, and the combination therapy is the same as in the experimental group.
Drug: R-GemOx
R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.
Other Names:
  • Gemcitabine Hydrochloride for Injection
  • Rituximab Injection
  • Oxaliplatin Injection
Drug: HMPL-760 Placebo
Patients will receive HMPL-760 placebo once daily (QD) orally.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Progression-free survival (PFS)
Time Frame: Up to approximately two years
Investigator-assessed progression-free survival (PFS) Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014). PFS is defined as the time from randomization to PD or death due to any cause, whichever occurs first.
Up to approximately two years
End of treatment (EOT)
Time Frame: Up to approximately two years
Tumor assessment data will continue to be collected. Tumor assessment data collected after end of treatment (EOT) will be used. Tumor assessment data collected during the study and after EOT will be included in the PFS analysis (treatment policy strategy).
Up to approximately two years
Systemic antitumor therapy
Time Frame: Up to approximately two years
Use of other systemic antitumor therapy before PD or death (in the absence of PD):Tumor assessment after use of other systemic antitumor therapy will not be included in the analysis. For patients using other anti-tumor therapy before PD or death (in absence of PD), PFS will be censored at the last evaluable tumor assessment before the use of other systematic anti-tumor therapy (hypothetical strategy).
Up to approximately two years
Overall survival (OS)
Time Frame: Up to approximately two years
OS is defined as the time from randomization to death due to any cause.
Up to approximately two years
systematic anti-tumor therapy
Time Frame: Up to approximately two years
OS data will continue to be collected after the other systematic anti-tumor therapy, and the OS data collected before and after other systematic anti-tumor therapy will be included in analysis (treatment policy strategy).
Up to approximately two years
Premature withdrawal from study treatment
Time Frame: Up to approximately two years
OS data will continue to be collected after the patient's premature withdrawal from study treatment, and the OS data collected during the study treatment and after EOT will be included in analysis (treatment policy strategy).
Up to approximately two years

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Independent review committee (IRC)-assessed PFS
Time Frame: Up to approximately two years
Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014).
Up to approximately two years
IRC- and investigator-assessed objective response rate (ORR)
Time Frame: Up to approximately two years
Objective Response Rate (ORR) is defined as the ratio of patients who reached complete response (CR) or partial response (PR)
Up to approximately two years
IRC- and investigator-assessed complete response rate (CRR)
Time Frame: Up to approximately two years
Complete response (CR) rate is defined as the ratio of patients with who reached complete response (CR)
Up to approximately two years
IRC- and investigator-assessed duration of response (DoR)
Time Frame: Up to approximately two years
For patients who reached complete response (CR) or partial response (PR), Duration of Response (DoR) is defined as the time from the first CR or PR until disease progression or death due to any cause, whichever occurs first
Up to approximately two years
IRC- and investigator-assessed clinical benefit rate (CBR)
Time Frame: Up to approximately two years
Defined as the ratio of patients with complete response (CR), partial response (PR), or stable disease (SD)
Up to approximately two years
IRC- and investigator-assessed time to response (TTR)
Time Frame: Up to approximately two years
Time To Response (TTR) is defined as the time from the start of treatment to the first objective response rate (ORR)
Up to approximately two years
Safety Endpoints
Time Frame: Up to approximately two years
  • Incidence and severity of treatment-emergent adverse events (TEAEs), incidence of treatment-emergent serious adverse events (TESAEs), incidence of TEAEs leading to permanent discontinuation, dose interruption, and dose reduction, and their correlation to study drug. The severity is determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 6.0 (NCI CTCAE 6.0).
  • Changes in laboratory tests, vital signs, 12-lead ECG, etc.
Up to approximately two years
PK characteristics of HMPL-760 in patients with R/R DLBCL when administered in combination with R-GemOx
Time Frame: At the end of Cycle 4 (each cycle is 21 days)]

including but not limited to steady-state plasma concentrations of HMPL-760 pre-dose [trough concentrations (Ctrough)] and post-dose (C1h and C2h); If possible, a population pharmacokinetic (PPK) model can be used to generate PK parameters. If necessary, it can also be combined with other studies for model analysis.

If possible, a population pharmacokinetic (PPK) model can be used to generate PK parameters. If necessary, it can also be combined with other studies for model analysis.
At the end of Cycle 4 (each cycle is 21 days)]

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Biomarker assessment
Time Frame: Up to approximately two years
Detect tumor driver gene mutations in tissue and blood samples, such as MYD88 and CD79B, etc, and explore the relationship between their mutation status and drug efficacy.
Up to approximately two years
To explore the metabolite profile of HMPL-760 in combination with R-GemOx in tumor patients
Time Frame: Up to approximately two years
Human metabolites of HMPL-760 when co-administered with R-GemOx
Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Time Frame: Up to approximately two years
maximum concentration in steady-state (Cmax,ss)
Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Time Frame: Up to approximately two years
time to maximum concentration in steady-state (Tmax,ss)
Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Time Frame: Up to approximately two years
Area Under the Curve at steady state refers to the area under the plasma concentration-time curve during a dosing interval at steady state conditions (AUC,ss)
Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Time Frame: Up to approximately two years
The rate at which the drug is eliminated from the body (CL/F) (if applicable )
Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Time Frame: Up to approximately two years
The distribution volume calculated based on the terminal elimination phase (Vz/F )(if applicable)
Up to approximately two years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Hutchmed

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Weili Zhao, Ruijin Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
March 20, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
April 30, 2028

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 30, 2028

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
January 28, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 6, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
February 13, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 20, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 17, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 2025-760-00CH1

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings